Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $15,057.88 in Stock

Key Points

• BD executive Michael Feld sold 76 shares at an average price of $198.13, generating $15,057.88. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 19,568 shares.
• Becton, Dickinson and Company shares fell 0.3% to $195.72, near their 52-week high of $200.47. The stock has a market capitalization of approximately $53.93 billion.
• The company exceeded quarterly earnings and revenue expectations, reporting $3.23 in adjusted EPS and $4.98 billion in revenue. Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $185.07.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 76 shares of the firm's stock in a transaction on Monday, October 26th. The shares were sold at an average price of $198.13, for a total value of $15,057.88. Following the transaction, the executive vice president owned 19,568 shares in the company, valued at approximately $3,877,007.84. This represents a 0.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, September 28th, Michael Feld sold 76 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $183.70, for a total value of $13,961.20.
• On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $188.49, for a total value of $31,100.85.

Becton, Dickinson and Company Stock Down 0.3%

Shares of NYSE BDX traded down $0.67 during trading hours on Tuesday, hitting $195.72. 618,536 shares of the stock were exchanged, compared to its average volume of 2,426,904. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47. The firm has a fifty day moving average price of $185.38 and a 200-day moving average price of $170.44. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market cap of $53.93 billion, a PE ratio of 58.94, a PEG ratio of 13.41 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company's revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a research note on Thursday, August 13th. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 28th. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Finally, Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Moderate Buy" and an average price target of $185.07.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth $3,721,533,000. Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the 2nd quarter worth about $474,993,000. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock worth $2,090,675,000 after acquiring an additional 1,887,224 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $247,372,000. Finally, Deutsche Bank AG purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $204,226,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.